secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2025-05-16T23:59:59+00:00
Accession:  0001193125-25-121296
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin acquires Inozyme for $4.00/share (~$270M cash); adds late-stage ENPP1 therapy
--------------------------------------------------------------------------------

- All-cash tender offer at $4.00 per share; total equity value ~$270M; expected to close Q3 2025.
- INOZYME's lead asset INZ-701 is a Phase 3 enzyme replacement for ENPP1 Deficiency; first pivotal data in children expected early 2026.
- Inozyme Board unanimously recommends; stockholders representing ~11.2% of shares have entered support agreements.
- BioMarin reaffirms FY2025 guidance and plan to achieve 40% Non-GAAP Operating Margin in 2026.
- Transaction not subject to financing condition; Goldman Sachs advised BioMarin, Centerview advised Inozyme.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312525121296/0001193125-25-121296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312525121296/d833625d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-121296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer